| |
|
|
|
|
|
|
|||
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 1195-1197. Prepublished online as a Blood First Edition Paper on September 30, 2004; DOI 10.1182/blood-2004-07-2972.
IMMUNOBIOLOGY
Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract |
|---|
|
|
|---|
B activity. These findings indicate that the majority of EOS and BS cases share the common genetic etiology of CARD15 mutations that cause constitutive NF-
B activation. | Introduction |
|---|
|
|
|---|
Blau syndrome (BS), also showing early-onset granulomatous arthritis, uveitis, and skin rash, is a rare familial disease transmitted in an autosomal dominant manner.3 By linkage analysis, the responsible locus for BS was mapped to chromosome 16, 4 in which CARD15 has recently been identified as the susceptibility gene.5 CARD15 (NOD2) is a member of the growing family of nucleotide-binding oligomerization domain (NOD) proteins and composed of 2 amino-terminal caspase recruitment domains (CARDs), one NOD, and carboxy-terminal leucine-rich repeats (LRRs).6,7 While mutations in LRRs are reportedly associated with Crohn disease (CD) and psoriatic arthritis, 8-10 3 types of missense point mutations in the NOD, 1000C>T (R334W in amino acid change), 1001G>A (R334Q), and 1405C>T (L469F), have been discovered in BS families.5,11,12
It has been discussed since the first report of BS whether EOS and BS are the same diseases.13 However, no direct evidence of their common origin has been shown and confusion still remains.14 In the first paper describing genetic abnormalities in BS, the authors recognized no CARD15 mutation in 2 EOS patients and therefore proposed a different etiology of BS and EOS.5 However, we have recently described a sporadic case of systemic granulomatosis syndrome with clinical features of EOS that showed the same CARD15 mutation as detected in BS.15 In this report, therefore, we retrospectively collected Japanese EOS cases and searched for CARD15 mutations, to further evaluate the relationship between EOS and CARD15 mutations.
| Study design |
|---|
|
|
|---|
The diagnosis of EOS was confirmed by the absence of family history of granuloma-forming diseases, as well as the typical clinical and histologic features. The agreement for genetic analysis was obtained from 10 Japanese EOS patients, whose clinical information is summarized in Table 1.15-20 Informed consent was provided according to the Declaration of Helsinki. The study was approved by the ethics committees of Kyoto University and the organizations where the patients were under medical treatment. Genomic DNA was extracted from peripheral blood of the patients, and all 12 exons of the CARD15 gene including exon-intron boundaries were amplified by polymerase chain reaction and sequenced. Genomic DNA of 100 healthy volunteers was examined for the mutations discovered in our patients.
|
Generation of CARD15 mutants and NF-
B luciferase assay
The wild-type CARD15 cDNA was generated from a healthy volunteer by reverse transcriptionpolymerase chain reaction. Each CARD15 mutant cDNA was generated using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and subcloned into p3xFLAG-CMV-14 vector (Sigma, St Louis, MO). HEK293T cells (1 x 105) were transfected with 1000 ng plasmids, containing 100 ng nuclear factor (NF)
B reporter plasmid (pNF-
B-Luc; BD Biosciences Clontech, Palo Alto, CA), 30 ng expression construct of a CARD15 variant, 10 ng internal control for normalization of transfection efficiency (pRL-TK; Toyo Ink, Tokyo, Japan), and the corresponding mock vector, using TransIT-293 Transfection Reagent (Mirus Bio, Madison, WI). The cells were cultured with or without 5 µg/mL muramyl dipeptide (MDP; Sigma) for 12 hours after transfection and measured for NF-
B activity using PicaGene Dual Luciferase Kit (Toyo Ink). Protein expression of each CARD15 variant was examined by Western blotting using anti-FLAG (8 amino acids; DYKDDDDK) M2 monoclonal antibody (Sigma).
| Results and discussion |
|---|
|
|
|---|
CARD15 is expressed intracellularly in phagocytic cells and recognizes MDP, a component of bacterial peptidoglycan, to induce immune responses through NF-
B activation.6,7,22,23 The BS-related CARD15 variants reportedly show increased basal MDP-independent NF-
B activity.24 Accordingly, the MDP-independent and -dependent NF-
B transactivation by the novel CARD15 mutations discovered in our EOS cases was examined in vitro to define their biologic effects. At equivalent protein expression levels, 5 novel CARD15 variants (H496L, T605P, N670K, M513T, and D382E) significantly increased the basal NF-
B activity compared with the wild-type CARD15, similar to the R334W found in both BS families and our EOS cases (Figure 1A, open bars). Although the A612T showed reduced basal NF-
B activity as reported previously, 24 cotransfection of D382E and A612T increased the basal NF-
B activity (Figure 1B, open bars), indicating the dominant positive effect of the D382E in case 9. Similar dominant positive effects of other 5 mutations were observed when cotransfected with the wild-type CARD15. In contrast, addition of a maximum dose of MDP (5 µg/mL) to each CARD15 mutant further elevated the NF-
B activity up to almost the same level as the case of the wild-type CARD15 (Figure 1A-B, filled bars). Collectively, all 6 combinations of CARD15 variants mimicking the genotype of our EOS patients showed increased basal NF-
B activity (Figure 1B, open bars) and shared the common biologic effect with the BS-related CARD15 variants. Although the basal NF-
B activation levels of these 6 CARD15 variants were divergent, no remarkable correlation could be observed between the basal NF-
B activity and the disease severity (Table 1).
|
Recently, an extensive in vitro CARD15 mutation study has revealed that P668H and I673P mutations in the C-terminal NOD region show the increased basal NF-
B activity and minimal elevation of the activity by addition of MDP.25 Here, we found 5 novel mutations with increased basal NF-
B activity after systematic analysis of Japanese EOS cases. Indeed, location and a biologic effect of the N670K are similar to those of the P668H and I673P, but the mutations we found were distributed through the whole NOD and showed no significant difference in NF-
B activity induced by the maximum dose of MDP.
In conclusion, our results clearly show that EOS is closely related with CARD15 mutations causing constitutive NF-
B activation and shares the common genetic etiology with BS. These findings strongly support the long-standing hypothesis that sporadic EOS and familial BS represent different types of the same juvenile systemic granulomatosis syndrome.13
| Acknowledgements |
|---|
| Footnotes |
|---|
Prepublished online as Blood First Edition Paper, September 30, 2004; DOI 10.1182/blood-2004-07-2972.
N. Kanazawa and I.O. contributed equally to this work.
An Inside Blood analysis of this article appears in the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nobuo Kanazawa, Department of Dermatology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Kyoto, Japan; e-mail: nkanazaw{at}kuhp.kyoto-u.ac.jp.
| References |
|---|
|
|
|---|
B. J Biol Chem. 2001;276: 4812-4818.Related Article in Blood Online:
This article has been cited by other articles:
![]() |
H. Sakai, S. Ito, R. Nishikomori, Y. Takaoka, T. Kawai, M. Saito, I. Okafuji, T. Yasumi, T. Heike, and T. Nakahata A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene Rheumatology, October 23, 2009; (2009) kep315v1. [Full Text] [PDF] |
||||
![]() |
O. Penack, O. M. Smith, A. Cunningham-Bussel, X. Liu, U. Rao, N. Yim, I.-K. Na, A. M. Holland, A. Ghosh, S. X. Lu, et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease J. Exp. Med., September 28, 2009; 206(10): 2101 - 2110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Okada, N. Konishi, M. Tsumura, K. Shirao, S. Yasunaga, H. Sakai, R. Nishikomori, Y. Takihara, and M. Kobayashi Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15 Rheumatology, June 1, 2009; 48(6): 706 - 707. [Full Text] [PDF] |
||||
![]() |
F. L. W. Takken and W. I. L. Tameling To Nibble at Plant Resistance Proteins Science, May 8, 2009; 324(5928): 744 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Mogensen Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses Clin. Microbiol. Rev., April 1, 2009; 22(2): 240 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Rosenzweig, T. Kawaguchi, T. M. Martin, S. R. Planck, M. P. Davey, and J. T. Rosenbaum Nucleotide Oligomerization Domain-2 (NOD2)-Induced Uveitis: Dependence on IFN-{gamma} Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1739 - 1745. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Rosenzweig, M. M. Jann, T. T. Glant, T. M. Martin, S. R. Planck, W. van Eden, P. J. S. van Kooten, R. A. Flavell, K. S. Kobayashi, J. T. Rosenbaum, et al. Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis J. Leukoc. Biol., April 1, 2009; 85(4): 711 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Marina-Garcia, L. Franchi, Y.-G. Kim, Y. Hu, D. E. Smith, G.-J. Boons, and G. Nunez Clathrin- and Dynamin-Dependent Endocytic Pathway Regulates Muramyl Dipeptide Internalization and NOD2 Activation J. Immunol., April 1, 2009; 182(7): 4321 - 4327. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stroh, A. Batra, R. Glauben, I. Fedke, U. Erben, A. Kroesen, M. M. Heimesaat, S. Bereswill, S. Girardin, M. Zeitz, et al. Nucleotide Oligomerization Domains 1 and 2: Regulation of Expression and Function in Preadipocytes J. Immunol., September 1, 2008; 181(5): 3620 - 3627. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huang, L. Zhao, K. Kim, D. S. Lee, and D. H. Hwang Inhibition of Nod2 Signaling and Target Gene Expression by Curcumin Mol. Pharmacol., July 1, 2008; 74(1): 274 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Marina-Garcia, L. Franchi, Y.-G. Kim, D. Miller, C. McDonald, G.-J. Boons, and G. Nunez Pannexin-1-Mediated Intracellular Delivery of Muramyl Dipeptide Induces Caspase-1 Activation via Cryopyrin/NLRP3 Independently of Nod2 J. Immunol., March 15, 2008; 180(6): 4050 - 4057. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wilmanski, T. Petnicki-Ocwieja, and K. S. Kobayashi NLR proteins: integral members of innate immunity and mediators of inflammatory diseases J. Leukoc. Biol., January 1, 2008; 83(1): 13 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gandotra, S. Jang, P. J. Murray, P. Salgame, and S. Ehrt Nucleotide-Binding Oligomerization Domain Protein 2-Deficient Mice Control Infection with Mycobacterium tuberculosis Infect. Immun., November 1, 2007; 75(11): 5127 - 5134. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fujisawa, N. Kambe, M. Saito, R. Nishikomori, H. Tanizaki, N. Kanazawa, S. Adachi, T. Heike, J. Sagara, T. Suda, et al. Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells Blood, April 1, 2007; 109(7): 2903 - 2911. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Schaffer, P. Chandra, B. R. Keegan, P. Heller, and H. T. Shin Widespread Granulomatous Dermatitis of Infancy: An Early Sign of Blau Syndrome Arch Dermatol, March 1, 2007; 143(3): 386 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Iannuzzi and B. A. Rybicki Genetics of Sarcoidosis: Candidate Genes and Genome Scans Proceedings of the ATS, January 1, 2007; 4(1): 108 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Simon and J. W. M. van der Meer Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R86 - R98. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Franchi, C. McDonald, T.-D. Kanneganti, A. Amer, and G. Nunez Nucleotide-Binding Oligomerization Domain-Like Receptors: Intracellular Pattern Recognition Molecules for Pathogen Detection and Host Defense J. Immunol., September 15, 2006; 177(6): 3507 - 3513. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. McDonald, F. F. Chen, V. Ollendorff, Y. Ogura, S. Marchetto, P. Lecine, J.-P. Borg, and G. Nunez A Role for Erbin in the Regulation of Nod2-dependent NF-{kappa}B Signaling J. Biol. Chem., December 2, 2005; 280(48): 40301 - 40309. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Watanabe, A Kitani, and W Strober NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease Gut, November 1, 2005; 54(11): 1515 - 1518. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||